<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pertussis infection in adolescents and adults: Treatment and prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pertussis infection in adolescents and adults: Treatment and prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pertussis infection in adolescents and adults: Treatment and prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Cornia, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Benjamin A Lipsky, MD, FACP, FIDSA, FRCP (London), FRCPS (Glasg)
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen B Calderwood, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jane Givens, MD, MSCE
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheila Bond, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 08, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H12882590">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pertussis, also known as "whooping cough," is a highly contagious acute respiratory illness caused by
         <em>
          Bordetella pertussis
         </em>
         . In the prevaccine era, the disease predominantly affected children &lt;10 years of age and usually manifested as a prolonged cough illness with one or more of the classical symptoms including inspiratory whoop, paroxysmal cough, and post-tussive emesis [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Since the introduction of pertussis vaccines, the epidemiology of reported pertussis infections has changed. In the United States in the 1990s, more than one-half of cases occurred in adolescents and adults [
         <a href="#rid2">
          2
         </a>
         ]. In 2015, the greatest proportion of cases was amongst adolescents aged 11 to 19 (32 percent) [
         <a href="#rid3">
          3
         </a>
         ]. These infected adolescents and adults serve as a reservoir for infection of infants and children, who more often experience serious pertussis-related morbidity and mortality. Because symptoms and signs in adolescents and adults are often nonspecific, clinicians may not consider the diagnosis of pertussis in patients presenting with a cough illness.
        </p>
        <p>
         Issues related to treatment and prevention of pertussis in adolescents and adults will be reviewed here. Issues related to treatment and prevention of pertussis in infants and children are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5997.html" rel="external">
          "Pertussis infection in infants and children: Treatment and prevention"
         </a>
         .)
        </p>
        <p>
         The pathogenesis, epidemiology, clinical manifestations, and diagnosis of this infection are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8043.html" rel="external">
          "Pertussis infection: Epidemiology, microbiology, and pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/8045.html" rel="external">
          "Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5995.html" rel="external">
          "Pertussis infection in infants and children: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12882597">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The United States Centers for Disease Control and Prevention (CDC) has published recommendations for treatment and postexposure prophylaxis of pertussis [
         <a href="#rid4">
          4
         </a>
         ]. Our approach is consistent with these recommendations  (
         <a class="graphic graphic_algorithm graphicRef132606" href="/z/d/graphic/132606.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1256788322">
         <span class="h2">
          Antibiotic therapy
         </span>
        </p>
        <p class="headingAnchor" id="H2600678617">
         <span class="h3">
          Indications
         </span>
        </p>
        <p class="headingAnchor" id="H1932085834">
         <span class="h4">
          Within three weeks of cough onset
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend antibiotic therapy for all patients with a clinical or microbiologic diagnosis of pertussis who present within three weeks of cough onset, because this is the highest risk period of transmission. This includes patients who present during the catarrhal phase (typically the first one to two weeks of illness) whose cough may not have paroxysmal features. Although the diagnosis of pertussis is rarely established, or even considered, during this early phase among adolescents and adults, it may be suspected in symptomatic individuals in outbreak settings or following contact with a patient with pertussis infection. (See
         <a class="medical medical_review" href="/z/d/html/8045.html" rel="external">
          "Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis", section on 'Approach to diagnosis'
         </a>
         .)
        </p>
        <p>
         Although antibiotic treatment at this stage in the illness (particularly after the catarrhal phase) may not affect the course of symptoms, it is effective in eradicating
         <em>
          B. pertussis
         </em>
         from infected individuals [
         <a href="#rid5">
          5
         </a>
         ], and thereby can reduce the spread of the infection to others. A small number of trials have evaluated antibiotic therapy for pertussis infection in children, mainly in the paroxysmal phase of illness. In a systematic review of these trials, antibiotic therapy was effective in eradicating
         <em>
          B. pertussis
         </em>
         from the nasopharynx, but did not alter the course of the disease [
         <a href="#rid5">
          5
         </a>
         ]. Observational studies, however, have suggested that treatment of pertussis is associated with a lower rate of secondary spread (eg, among households or institutions) [
         <a href="#rid6">
          6-8
         </a>
         ]. A small retrospective cohort study of adolescents and adults from Japan found that patients who received early administration (defined as within 11 days of cough onset) of a macrolide antibiotic had a significantly shorter duration of cough than those who did not [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2846345375">
         <span class="h4">
          After three weeks of cough onset
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since persistent cough is related to local tissue damage from
         <em>
          B. pertussis
         </em>
         rather than an ongoing infection, we do not routinely prescribe antibiotic therapy after three weeks of cough onset in patients with clinical or microbiologic diagnosis of pertussis. An exception is pregnant women, particularly those who are near term, in whom antibiotic therapy up to six weeks after cough onset is appropriate to prevent transmission to neonates [
         <a href="#rid10">
          10
         </a>
         ]. Additionally, we favor antibiotic therapy up to six weeks after cough onset for patients with asthma, chronic obstructive pulmonary disease, or immunocompromising condition, and for those ≥65 years old. Although limited, emerging data indicate that pertussis-related morbidity, including the risk for hospitalization, is highest in these specific subgroups [
         <a href="#rid11">
          11-14
         </a>
         ]. Thus, we feel that antibiotic treatment for these groups is appropriate although the benefit remains uncertain.
        </p>
        <p>
         Antibiotic therapy is not warranted after six weeks of cough onset for any adolescent or adult. Based on limited data, most individuals appear to clear pertussis infection within six weeks, even without antibiotic treatment [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2160264697">
         <span class="h3">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the highly contagious nature of the disease and the delay in availability of culture test results (up to 7 to 10 days), in accordance with CDC recommendations, we suggest initiating empiric antibiotic therapy once there is sufficient clinical suspicion of pertussis without awaiting diagnostic testing results.
        </p>
        <p>
         The clinical case definition of pertussis is a cough illness lasting at least two weeks without an apparent cause, with at least one of the following symptoms: paroxysms of coughing, inspiratory whoop, or post-tussive emesis [
         <a href="#rid16">
          16,17
         </a>
         ]. Patients with a history of potential exposure to pertussis may warrant clinical suspicion despite less characteristic symptoms. (See
         <a class="medical medical_review" href="/z/d/html/8045.html" rel="external">
          "Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12882611">
         <span class="h3">
          Antibiotic selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Either
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         is the recommended antibiotic regimen for pertussis infection in adolescents and adults [
         <a href="#rid4">
          4,10
         </a>
         ]. In patients unable to take these macrolide agents,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX) is an acceptable alternative. Azithromycin is the treatment of choice in pregnancy. The antibiotic regimens for treatment and postexposure prophylaxis are identical. (See
         <a class="local">
          'Postexposure prophylaxis'
         </a>
         below.)
        </p>
        <p>
         Doses for nonpregnant adults and adolescents are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         orally for five days (500 mg day 1, followed by 250 mg days 2 through 5).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         500 mg orally twice daily for seven days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         TMP-SMX one double-strength tablet orally twice daily for 14 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In individuals who are pregnant,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         is the preferred agent, when available.
        </p>
        <p>
        </p>
        <p>
         Macrolides are highly effective at eradicating
         <em>
          B. pertussis
         </em>
         from the nasopharynx [
         <a href="#rid4">
          4,18
         </a>
         ]. A small number of trials have evaluated antibiotic therapy for pertussis infection in children, mainly in the paroxysmal phase of illness. In a systematic review of antibiotic trials in children, short-term macrolide therapy (
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         for three to five days or
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         for seven days) was as effective at eradicating B. pertussis as long-term treatment (erythromycin for 10 to 14 days) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         are the preferred agents, given both their relative stability at gastric acid pH levels and high oral bioavailability.
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          Erythromycin
         </a>
         is no longer recommended because it requires four times daily dosing and is more frequently associated with gastrointestinal toxicity (abdominal cramping, nausea, vomiting, and diarrhea). In a systematic review of trials among children, when treatment with azithromycin or clarithromycin was compared with erythromycin, there was no difference in rates of microbial eradication but fewer side effects with azithromycin and clarithromycin [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         is contraindicated for persons with a prior history of cholestatic jaundice or hepatitis specifically associated with its use [
         <a href="#rid19">
          19
         </a>
         ]. Like all macrolide antibiotics, azithromycin has also been associated with electrocardiographic QT prolongation, as well as a small absolute increase in cardiovascular deaths, particularly in those at high baseline risk [
         <a href="#rid20">
          20
         </a>
         ]. Because
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         inhibit the cytochrome P450 enzyme system, concomitant use of any other drug metabolized by this system may result in increased macrolide levels with resultant toxicity, including QT interval prolongation and sudden cardiac death [
         <a href="#rid21">
          21
         </a>
         ]. In these situations, alternative therapy with TMP-SMX may be preferable. Drug interactions can be checked through the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         within UpToDate.
        </p>
        <p>
         While in vitro susceptibility of
         <em>
          B. pertussis
         </em>
         to other antibiotic agents including fluoroquinolones and tetracyclines has been demonstrated [
         <a href="#rid22">
          22-26
         </a>
         ], there are no clinical data to support their use. It is reasonable to use these in patients who have contraindications or intolerance to macrolides and TMP-SMX. Although
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         has in vitro activity against
         <em>
          B. pertussis
         </em>
         , we do not recommend using it as it does not effectively eradicate the organism from the nasopharynx [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         Routine antimicrobial susceptibility testing is not needed for
         <em>
          B. pertussis
         </em>
         since macrolide resistance is relatively uncommon [
         <a href="#rid4">
          4
         </a>
         ]. However, in cases of apparent clinical failure with macrolide therapy, it may be useful to test any cultured isolates of
         <em>
          B. pertussis
         </em>
         for macrolide susceptibility. This can be done using standard methodology, including E-test and disk diffusion assays [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         A Finnish study including 148
         <em>
          B. pertussis
         </em>
         strains isolated between 2006 and 2017 found no resistant organisms, or any increase in resistance levels, to either macrolides or quinolones [
         <a href="#rid29">
          29
         </a>
         ]. Similarly, among isolates in the Czech Republic from 1967 to 2015, the minimum inhibitory concentrations of
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         , and TMP-SMX to
         <em>
          B. pertussis
         </em>
         were unchanged over time [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         <em>
          B. parapertussis
         </em>
         may cause a pertussis-like illness and requires PCR testing to distinguish it from
         <em>
          B. pertussis
         </em>
         ; limited evidence suggests prompt antibiotic treatment may shorten illness duration and transmission of
         <em>
          B. parapertussis
         </em>
         [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12882653">
         <span class="h2">
          Cough management
         </span>
         <span class="headingEndMark">
          —
         </span>
         The paroxysmal cough of pertussis may be severe and protracted, representing the main cause of associated morbidity. The cough likely results from destruction of upper respiratory ciliated cells by pertussis toxins; this leads to trickling of secretions from the nasopharynx into the larynx, triggering the cough reflex. Cough resolution requires regrowth of these cells, which typically takes many weeks.
        </p>
        <p>
         For patients who desire pharmacologic therapy for cough, we generally select
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         because of its favorable adverse effect profile. However, selection of a cough suppressant should take into account patient comorbidities and drug interactions. As an example, selective serotonin reuptake inhibitors (SSRIs) may enhance the serotonergic effect of dextromethorphan (eg, precipitate serotonin syndrome).
        </p>
        <p>
         We avoid prescribing other agents, particularly opioids, as the risk of adverse effects most likely outweighs any benefit and the cough, although troublesome and protracted, is self-limited. Untested home remedies that may offer relief to some include keeping well hydrated, using a mist vaporizer, avoiding cough triggers (eg, smoke, strong chemicals, allergens), and eating frequent small meals to help avoid vomiting.
        </p>
        <p>
         A systematic review, including 12 trials of various treatments, concluded that there is insufficient evidence to allow recommendations for symptomatic treatment of cough in the setting of pertussis [
         <a href="#rid32">
          32
         </a>
         ]. A more recent narrative review of chronic refractory cough (of various causes) recommended considering treatment with the gamma aminobutyric acid analogs
         <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">
          gabapentin
         </a>
         or
         <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">
          pregabalin
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12882660">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preventive measures against pertussis include vaccination, postexposure prophylaxis, and isolation of patients with known or suspected pertussis.
        </p>
        <p class="headingAnchor" id="H12882667">
         <span class="h2">
          Vaccination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial vaccines developed following the isolation of the
         <em>
          B. pertussis
         </em>
         organism in the early 1900s contained killed whole-cell
         <em>
          B. pertussis
         </em>
         organisms. Subsequently, acellular pertussis vaccines containing purified components of the organism were developed. The acellular vaccines have a more favorable side effect profile, though the whole-cell vaccine may induce more durable immunity [
         <a href="#rid34">
          34-37
         </a>
         ]. Countries with universal childhood vaccination programs have observed dramatic reductions in the incidence of pertussis.
        </p>
        <p>
         Acellular vaccines were first licensed for use in the United States in 1991 [
         <a href="#rid38">
          38,39
         </a>
         ]. Routine childhood vaccination in the United States is performed with the diphtheria, tetanus toxoids, and pertussis (DTaP) vaccine ("a" designating acellular pertussis vaccine combined with tetanus and diphtheria toxoids) [
         <a href="#rid40">
          40
         </a>
         ]. In the United States, standard vaccination for pertussis is recommended for all children, followed by routine booster dosing in adolescence and adulthood. Vaccination in infants and children is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2844.html" rel="external">
          "Diphtheria, tetanus, and pertussis immunization in children 6 weeks through 6 years of age"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2838.html" rel="external">
          "Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1988363607">
         <span class="h3">
          Previously unvaccinated individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         For adolescents (up to 18 years old) who have not been fully immunized with DTaP, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) should be given as the first dose of the "catch-up series;" additional doses of tetanus and diphtheria toxoid-containing vaccine and the interval of administration depend on the prior vaccination history  (
         <a class="graphic graphic_table graphicRef117917" href="/z/d/graphic/117917.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid40">
          40
         </a>
         ]. For unvaccinated adults, a three-vaccine series is recommended; the preferred vaccination schedule is Tdap, followed by either Td or Tdap at least four weeks later, then either Td or Tdap again in 6 to 12 months [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3296861715">
         <span class="h3">
          Tdap booster for previously vaccinated individuals
         </span>
         <span class="headingEndMark">
          —
         </span>
         Immunity to pertussis infection wanes 5 to 10 years after completing the childhood vaccination series. Because of steadily increasing cases of pertussis in adolescents and adults, in 2005 the United States Advisory Committee on Immunization Practices (ACIP) recommended booster vaccination for all adolescents and adults [
         <a href="#rid41">
          41,42
         </a>
         ]. This is particularly important for those with close contacts with infants, as well as for health care workers and pregnant women during each pregnancy  (
         <a class="graphic graphic_figure graphicRef82634" href="/z/d/graphic/82634.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1246386494">
         <span class="h4">
          Adolescents aged 11 to 18 years
         </span>
         <span class="headingEndMark">
          —
         </span>
         A single booster immunization with Tdap (Boostrix or Adacel [brand names]) should be administered, preferably at 11 or 12 years of age [
         <a href="#rid40">
          40
         </a>
         ]. The use of Tdap for adolescents is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2838.html" rel="external">
          "Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3825292781">
         <span class="h4">
          Nonpregnant adults 19 years or older
         </span>
         <span class="headingEndMark">
          —
         </span>
         A single Tdap booster dose should be administered to adults older than 19 years who have not previously received Tdap (ie, after age 11 years), as recommended by the ACIP [
         <a href="#rid43">
          43
         </a>
         ]. Vaccination is particularly important in those adults who have close contact with infants (eg, grandparents or childcare providers), health care workers, and those who are obese or who have pre-existing asthma [
         <a href="#rid44">
          44
         </a>
         ]. Tdap booster vaccination is appropriate even for patients who have had a recent clinical episode of pertussis.
        </p>
        <p>
         Tdap should be administered regardless of the interval since the last dose of Td. This represents a change from previous ACIP guidelines, which recommended that Tdap be given a minimum of two years after the last dose of Td in most cases. If it is not possible to determine whether an adult has had a Tdap booster, it is reasonable to administer a dose and ensure that it is appropriately documented. Subsequent tetanus booster doses, in the form of Td, should be given at 10-year intervals throughout adulthood. (See
         <a class="medical medical_review" href="/z/d/html/3897.html" rel="external">
          "Tetanus-diphtheria toxoid vaccination in adults", section on 'Routine adult immunization'
         </a>
         .)
        </p>
        <p>
         The US Food and Drug Administration (FDA) has approved Boostrix for individuals ≥10 years of age and approved Adacel for individuals 10 to 64 years of age [
         <a href="#rid45">
          45
         </a>
         ]. While either of the available Tdap formulations (Boostrix or Adacel [brand names]) may be administered to a person ≥65 years, Boostrix is preferred because it has FDA approval for this age group [
         <a href="#rid46">
          46
         </a>
         ]. However, to avoid missing an opportunity to vaccinate an individual ≥65 years, providers should administer whichever Tdap vaccine is available. Based on review of published and unpublished data, the ACIP 2012 recommendations noted that the safety and immunogenicity of Boostrix and Adacel in adults ≥65 years are comparable [
         <a href="#rid46">
          46
         </a>
         ]. Available data have confirmed that immunization of adults aged ≥65 years did not have untoward safety consequences [
         <a href="#rid47">
          47,48
         </a>
         ].
        </p>
        <p>
         Booster vaccination with Tdap is recommended because childhood pertussis vaccination does not provide lifelong immunity and the incidence of pertussis infection has been rising among adolescents and adults. (See
         <a class="medical medical_review" href="/z/d/html/2838.html" rel="external">
          "Diphtheria, tetanus, and pertussis immunization in children 7 through 18 years of age", section on 'Duration of immunity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8043.html" rel="external">
          "Pertussis infection: Epidemiology, microbiology, and pathogenesis", section on 'Evolving epidemiology'
         </a>
         .)
        </p>
        <p>
         The safety and immunogenicity of acellular pertussis vaccines in adolescents and adults have been demonstrated in randomized, placebo-controlled trials [
         <a href="#rid43">
          43,49-56
         </a>
         ]. In the largest randomized controlled trial, which included 4480 adolescents and adults (aged 11 through 64 years), Tdap elicited a robust immune response with an overall safety profile similar to that of Td [
         <a href="#rid54">
          54
         </a>
         ]. The efficacy of acellular pertussis vaccine (without Td) among adolescents and adults has also been demonstrated in a randomized trial [
         <a href="#rid55">
          55
         </a>
         ]. Among healthy individuals between the ages of 15 and 65 years who received acellular pertussis vaccine (rather than the control
         <a class="drug drug_general" data-topicid="8519" href="/z/d/drug information/8519.html" rel="external">
          hepatitis A vaccine
         </a>
         ), the efficacy was 92 percent (95% CI 32-99). In a nested case-control study of older adults (mean age 61 years), Tdap reduced polymerase chain reaction-confirmed pertussis infection by 52 percent [
         <a href="#rid57">
          57
         </a>
         ]. A study indicates that the acellular pertussis booster vaccination induces responses in older adults similar to those in children [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         In the United States, only a single Tdap is recommended in nonpregnant patients older than 11 years for the specific purpose of preventing pertussis since there is no evidence that additional Tdap vaccination will reduce the overall burden of pertussis or be cost effective [
         <a href="#rid40">
          40
         </a>
         ]. However, the ACIP allows for either Td or Tdap to be used for subsequent tetanus and diphtheria decennial booster doses to allow providers more flexibility in vaccine choice [
         <a href="#rid59">
          59
         </a>
         ]. ACIP notes that there is still uncertainty over what impact receipt of multiple doses of Tdap would have on pertussis transmission and prevention.
        </p>
        <p>
         However, several European countries recommend booster Tdap doses every 10 years for adults for the express purpose of preventing pertussis [
         <a href="#rid60">
          60
         </a>
         ]. The rationale for this is that the effectiveness of the Tdap vaccine in adolescents has been shown to wane within two to four years after administration [
         <a href="#rid36">
          36
         </a>
         ]. This likely contributes to the increased incidence of pertussis observed in adolescents.
        </p>
        <p>
         Administration of a second Tdap dose to young adults 10 years after the first dose appears to be safe and immunogenic [
         <a href="#rid61">
          61
         </a>
         ]. As an example, in a randomized controlled trial in 1330 adults aged 18 to 65 years who had received a dose of Tdap 8 to 12 years previously, administration of Tdap or Td resulted in similar rates of adverse events; those in the Tdap group had robust antibody responses to the pertussis antigens [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
         Rates of Tdap coverage among adults with children in their household appear to be low but are substantially higher for patients whose providers recommend the vaccine, highlighting the important role of the provider [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         Health care personnel (HCP) are at risk for exposure to pertussis and for exposing vulnerable patients when they are infectious. Numerous nosocomial outbreaks of pertussis have been attributed to HCP exposure, with considerable associated morbidity and occasional mortality [
         <a href="#rid41">
          41,64-66
         </a>
         ]. Tdap vaccination in adult health care workers is effective in controlling nosocomial outbreaks of pertussis and is less costly than a hospital outbreak [
         <a href="#rid41">
          41,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1752694355">
         <span class="h4">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         Issues related to pertussis vaccination in pregnancy are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/442.html" rel="external">
          "Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1655575698">
         <span class="h3">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contraindications to the Tdap vaccine include prior severe allergic reaction (anaphylaxis) after a vaccine dose or to a vaccine component or a history of encephalopathy (not attributable to an alternate cause) that occurred within seven days of a pertussis-containing vaccination. Individuals with an apparent severe allergic reaction to a vaccine should be referred to an allergist to determine the responsible allergen and for advice regarding future vaccination [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12882702">
         <span class="h3">
          International strategies
         </span>
         <span class="headingEndMark">
          —
         </span>
         An international collaboration, the Global Pertussis Initiative (GPI), has assessed various vaccination strategies including routine childhood immunizations, universal adolescent, adult, and preschool booster vaccination, as well as selective vaccination of health care workers, childcare workers, new mothers, and close contacts of newborns ("cocooning") [
         <a href="#rid68">
          68
         </a>
         ]. Providing indirect protection through Tdap vaccination to adults is the premise for the “cocooning” strategy to prevent pertussis in young infants at highest risk for severe pertussis, but evidence suggests that vaccination with acellular pertussis vaccines does not prevent transmission [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         Given the global variability in pertussis epidemiology and health care resources, a uniform set of guidelines for all countries is not feasible. The GPI does, however, offer some region-specific strategies to help improve diagnosis, surveillance and vaccine uptake [
         <a href="#rid69">
          69-74
         </a>
         ]. To increase vaccine uptake in adults, another international group of experts emphasized the importance of actively recommending vaccination, involving pharmacies and other vaccination centers in vaccine initiatives, educating the general public on pertussis burden and the benefits of vaccination, as well as harmonizing vaccination guidelines [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12882709">
         <span class="h2">
          Postexposure prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest that all household contacts of a person with pertussis receive postexposure antibiotics, regardless of their vaccination history. Prior Tdap booster is not sufficiently protective to eliminate the need for antibiotic prophylaxis [
         <a href="#rid4">
          4
         </a>
         ]. Even young, healthy adults who have been fully vaccinated (including with a booster dose within five years) can become infected during an outbreak [
         <a href="#rid76">
          76
         </a>
         ]. For others who have close contact with a person with pertussis, postexposure prophylaxis is recommended for those who are at high risk for severe pertussis illness or have close contact with persons at high risk. The United States Centers for Disease Control and Prevention defines high-risk persons as: infants, women in the third trimester of pregnancy, and those with chronic health conditions that may increase the likelihood of pertussis-related morbidity (eg, immunocompromising condition, chronic lung disease) [
         <a href="#rid77">
          77
         </a>
         ]. Exposed individuals, especially those with an incomplete vaccination history, should be closely observed for symptoms and signs of pertussis for three weeks after contact.
        </p>
        <p>
         Close contact is defined as:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Face-to-face exposure within three feet of a symptomatic patient
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Direct contact with respiratory, nasal, or oral secretions
        </p>
        <p>
        </p>
        <p>
         Regimens for postexposure prophylaxis are the same as for treatment. (See
         <a class="local">
          'Antibiotic selection'
         </a>
         above.)
        </p>
        <p>
         Administration of postexposure antibiotic therapy to an asymptomatic person who has had contact with a person with pertussis who is within 21 days of onset of cough can potentially prevent symptomatic infection [
         <a href="#rid78">
          78
         </a>
         ]. In one retrospective analysis, implementation of postexposure prophylaxis as part of an institutional protocol was associated with termination of a pertussis outbreak [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Postexposure immunization, either passive with immunoglobulin [
         <a href="#rid79">
          79
         </a>
         ] or active with pertussis vaccine, does
         <strong>
          not
         </strong>
         protect contacts from infection [
         <a href="#rid80">
          80
         </a>
         ]. For adolescents and adults with prior pertussis infection or exposure, subsequent vaccination should be administered based on standard recommendations [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3086397638">
         <span class="h2">
          Infection control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hospitalized patients with
         <em>
          B. pertussis
         </em>
         should be placed on droplet precautions (in addition to standard precautions). (See
         <a class="medical medical_review" href="/z/d/html/4042.html" rel="external">
          "Infection prevention: Precautions for preventing transmission of infection", section on 'Droplet precautions'
         </a>
         .)
        </p>
        <p>
         As above, postexposure prophylaxis is recommended for health care workers who have been exposed to pertussis and are either at high risk for severe pertussis illness or have close contact with persons who are at high risk [
         <a href="#rid77">
          77
         </a>
         ] (see
         <a class="local">
          'Postexposure prophylaxis'
         </a>
         above). Other exposed health care workers who do not meet those criteria or have less direct contact may be closely monitored for 21 days after exposure and treated if they develop signs or symptoms of pertussis. If health care workers develop symptoms of pertussis, they should be excluded from work for at least the first five days of antimicrobial therapy.
        </p>
        <p>
         Patients with
         <em>
          B. pertussis
         </em>
         infection should avoid contact with young children and infants, particularly those who are unimmunized or incompletely immunized, until they have completed at least five days of appropriate antibiotic therapy.
        </p>
        <p>
         In addition, patients with
         <em>
          B. pertussis
         </em>
         infection working in schools, daycare centers, or health care facilities should not return to work until completing at least five days of appropriate antibiotic therapy [
         <a href="#rid10">
          10,18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H507180922">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109611.html" rel="external">
          "Society guideline links: Pertussis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/109228.html" rel="external">
          "Society guideline links: Immunizations in children and adolescents"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/110427.html" rel="external">
          "Society guideline links: Immunizations in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19805909">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/86733.html" rel="external">
          "Patient education: Tdap vaccine (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12882723">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         − Adolescents and adults with pertussis serve as a reservoir for infection of infants and young children, who have the highest risk of serious pertussis-related morbidity and mortality. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Indications for treatment
         </strong>
         – Pertussis is a highly contagious acute bacterial respiratory illness. The primary reason for antibiotic treatment is to reduce transmission to others, particularly to those at risk for severe disease (eg, neonates, immunocompromised patients).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Indications for antibiotic treatment vary based on the duration of illness, pregnancy, and risk factors for increased morbidity  (
         <a class="graphic graphic_algorithm graphicRef132606" href="/z/d/graphic/132606.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For cough duration &lt;3 weeks, antibiotics are indicated
         </strong>
         – For adolescents or adults with a clinical or microbiologic diagnosis of pertussis and cough duration of &lt;3 weeks, we suggest antibiotic therapy  (
         <a class="graphic graphic_algorithm graphicRef132606" href="/z/d/graphic/132606.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This is the period of highest risk for transmission  (
         <a class="graphic graphic_figure graphicRef141240" href="/z/d/graphic/141240.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For cough duration ≥3 weeks but &lt;6 weeks, antibiotics are appropriate for selected patients –
         </strong>
         For most patients who present with ≥3 weeks of cough duration, we do not routinely treat with antibiotics because persistent cough is more likely related to local tissue damage than ongoing infection. Exceptions include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pregnant women
         </strong>
         – For pregnant individuals near term, we suggest antibiotic therapy for those presenting &lt;6 weeks following cough onset (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Shedding of
         <em>
          Bordetella pertussis
         </em>
         has been reported up to six weeks after illness onset, and treatment is given to prevent transmission to neonates. (See
         <a class="local">
          'After three weeks of cough onset'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Patients at risk for severe disease
         </strong>
         – For adolescents or adults who have chronic lung disease (eg, asthma, chronic obstructive pulmonary disease), immunocompromising conditions, or who are ≥65 years old, we suggest antibiotic therapy for those presenting &lt;6 weeks following cough onset (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Pertussis-related morbidity appears highest in these subgroups, and we feel treatment is appropriate despite the uncertain benefits. (See
         <a class="local">
          'After three weeks of cough onset'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Macrolides are preferred therapy
         </strong>
         – Macrolides are highly effective at eradicating
         <em>
          B. pertussis
         </em>
         from the nasopharynx. (See
         <a class="local">
          'Antibiotic selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who warrant antibiotic therapy for pertussis, we suggest
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         is the treatment of choice in pregnancy; the safety of
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         is uncertain.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For nonpregnant patients who cannot tolerate macrolides,
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         is an acceptable alternative. Dosing is outlined in the algorithm and table  (
         <a class="graphic graphic_algorithm graphicRef132606" href="/z/d/graphic/132606.html" rel="external">
          algorithm 1
         </a>
         and
         <a class="graphic graphic_table graphicRef75339" href="/z/d/graphic/75339.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cough management
         </strong>
         – For patients who desire pharmacologic therapy for cough, we generally select
         <a class="drug drug_general" data-topicid="8893" href="/z/d/drug information/8893.html" rel="external">
          dextromethorphan
         </a>
         . We avoid prescribing other agents, particularly opioids, as the risk of adverse effects most likely outweighs any benefit. In all cases, selection of a cough suppressant should take into account patient comorbidities and drug interactions (eg, dextromethorphan may enhance the serotonergic effect of selective serotonin reuptake inhibitors [SSRIs]). (See
         <a class="local">
          'Cough management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vaccination
         </strong>
         − In the United States, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) is routinely recommended at age 11 through 12 years. For nonpregnant adolescents and adults who have not previously received Tdap at that time, we recommend booster vaccination with Tdap (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Vaccination is particularly important for individuals who have close contact with infants aged younger than one year (such as grandparents, childcare providers, and health care providers). (See
         <a class="local">
          'Tdap booster for previously vaccinated individuals'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Tdap vaccination in pregnant individuals is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/442.html" rel="external">
          "Immunizations during pregnancy", section on 'Tetanus, diphtheria, and pertussis vaccination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postexposure prophylaxis
         </strong>
         −
         <strong>
         </strong>
         We suggest postexposure antibiotic prophylaxis for the following individuals (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Household contacts of patients with pertussis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals who had close contact to a patient with pertussis and are at risk for severe pertussis illness (eg, infants, women in the third trimester of pregnancy, and those with chronic health conditions such as an immunocompromising condition or chronic lung disease)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Individuals (including health care personnel) who had close contact to a patient with pertussis and have close contact with individuals at risk for severe pertussis illness
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The prophylaxis regimen is the same as the treatment regimen  (
         <a class="graphic graphic_table graphicRef75339" href="/z/d/graphic/75339.html" rel="external">
          table 2
         </a>
         ). Prior vaccination with Tdap should not be considered sufficiently protective to eliminate the need for chemoprophylaxis. (See
         <a class="local">
          'Postexposure prophylaxis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection control and return to work
         </strong>
         − Patients with pertussis should avoid contact with individuals at risk for severe disease until they have completed at least five days of effective antibiotic therapy or at least six weeks have passed since onset of cough. This includes young children and infants, those ≥65 years old, immunocompromised persons, and persons with chronic lung disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients working in schools, daycare centers, or health care facilities should not return to work until they have completed five days of antibiotic treatment or at least six weeks have passed since onset of cough. (See
         <a class="local">
          'Infection control'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H18284597">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Christopher A Ohl, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Güriş D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Pertussis--United States, 1997-2000. MMWR Morb Mortal Wkly Rep 2002; 51:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams DA, Thomas KR, Jajosky RA, et al. Summary of Notifiable Infectious Diseases and Conditions - United States, 2015. MMWR Morb Mortal Wkly Rep 2017; 64:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiwari T, Murphy TV, Moran J, National Immunization Program, CDC. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 2005; 54:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Altunaiji S, Kukuruzovic R, Curtis N, Massie J. Antibiotics for whooping cough (pertussis). Cochrane Database Syst Rev 2007; :CD004404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von König CH. Use of antibiotics in the prevention and treatment of pertussis. Pediatr Infect Dis J 2005; 24:S66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steketee RW, Wassilak SG, Adkins WN Jr, et al. Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled. J Infect Dis 1988; 157:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sprauer MA, Cochi SL, Zell ER, et al. Prevention of secondary transmission of pertussis in households with early use of erythromycin. Am J Dis Child 1992; 146:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amemiya T, Iwakami SI. Effects of Early Administration of Macrolides on Whooping Cough in Adolescents and Adults: A Single-center Retrospective Cohort Study. Intern Med 2021; 60:3081.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Pertussis (Whooping Cough): Treatment. http://www.cdc.gov/pertussis/clinical/treatment.html (Accessed on June 27, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182:174.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karki S, McIntyre P, Newall AT, et al. Risk factors for pertussis hospitalizations in Australians aged 45 years and over: A population based nested case-control study. Vaccine 2015; 33:5647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buck PO, Meyers JL, Gordon LD, et al. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect 2017; 145:2109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mbayei SA, Faulkner A, Miner C, et al. Severe Pertussis Infections in the United States, 2011-2015. Clin Infect Dis 2019; 69:218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwantes W, Joynson DH, Williams WO. Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan. J Hyg (Lond) 1983; 90:149.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Pertussis (Whooping Cough). https://www.cdc.gov/pertussis/surv-reporting.html (Accessed on October 03, 2018).
         </li>
         <li class="breakAll">
          World Health Organization. Immunization, Vaccines and Biologicals. http://www.who.int/immunization/monitoring_surveillance/en/ (Accessed on October 03, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergquist SO, Bernander S, Dahnsjö H, Sundelöf B. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J 1987; 6:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez MA, Vuppalanchi R, Fontana RJ, et al. Clinical and histologic features of azithromycin-induced liver injury. Clin Gastroenterol Hepatol 2015; 13:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerr JR, Preston NW. Current pharmacotherapy of pertussis. Expert Opin Pharmacother 2001; 2:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe JE, Dalhoff A, Pfründer D. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin. Antimicrob Agents Chemother 1998; 42:1868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mortensen JE, Rodgers GL. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis. J Antimicrob Chemother 2000; 45 Suppl 1:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felmingham D, Farrell DJ. In vitro activity of telithromycin against Gram-negative bacterial pathogens. J Infect 2006; 52:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horiba K, Nishimura N, Gotoh K, et al. Clinical manifestations of children with microbiologically confirmed pertussis infection and antimicrobial susceptibility of isolated strains in a regional hospital in Japan, 2008-2012. Jpn J Infect Dis 2014; 67:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trollfors B. Effect of erythromycin and amoxycillin on Bordetella pertussis in the nasopharynx. Infection 1978; 6:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoppe JE. Susceptibility testing of Bordetella pertussis. J Clin Microbiol 1998; 36:1465.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lönnqvist E, Barkoff AM, Mertsola J, He Q. Antimicrobial susceptibility testing of Finnish Bordetella pertussis isolates collected during 2006-2017. J Glob Antimicrob Resist 2018; 14:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jakubů V, Zavadilová J, Fabiánová K, Urbášková P. Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015. Cent Eur J Public Health 2017; 25:282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koepke R, Bartholomew ML, Eickhoff JC, et al. Widespread Bordetella parapertussis Infections-Wisconsin, 2011-2012: Clinical and Epidemiologic Features and Antibiotic Use for Treatment and Prevention. Clin Infect Dis 2015; 61:1421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang K, Bettiol S, Thompson MJ, et al. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev 2014; :CD003257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visca D, Beghè B, Fabbri LM, et al. Management of chronic refractory cough in adults. Eur J Intern Med 2020; 81:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witt MA, Arias L, Katz PH, et al. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013; 56:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein NP, Bartlett J, Fireman B, et al. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics 2013; 131:e1716.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Acosta AM, DeBolt C, Tasslimi A, et al. Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic. Pediatrics 2015; 135:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carvalho CFA, Andrews N, Dabrera G, et al. National Outbreak of Pertussis in England, 2011-2012: A Case-control Study Comparing 3-Component and 5-Component Acellular Vaccines With Whole-cell Pertussis Vaccines. Clin Infect Dis 2020; 70:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1992; 41:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use--supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1992; 41:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2018; 67:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep 2006; 55:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keitel WA, Muenz LR, Decker MD, et al. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 1999; 180:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu BC, McIntyre P, Kaldor JM, et al. Pertussis in older adults: prospective study of risk factors and morbidity. Clin Infect Dis 2012; 55:1450.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration: Approved Products--Adacel http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm172481.htm (Accessed on April 09, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control and Prevention (CDC). Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Adults Aged 65 Years and Older - Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 2012; 61:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moro PL, Yue X, Lewis P, et al. Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010. Vaccine 2011; 29:9404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tseng HF, Sy LS, Qian L, et al. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis 2013; 56:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halperin SA, Smith B, Russell M, et al. An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults. Vaccine 2000; 18:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothstein EP, Anderson EL, Decker MD, et al. An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates. Vaccine 1999; 17:2999.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van der Wielen M, Van Damme P, Joossens E, et al. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults. Vaccine 2000; 18:2075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tran Minh NN, He Q, Edelman K, et al. Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults. Vaccine 2000; 18:1971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2000; 19:628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005; 293:3003.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward JI, Cherry JD, Chang SJ, et al. Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 2005; 353:1555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gidengil C, Goetz MB, Newberry S, et al. Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Vaccine 2021; 39:3696.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu BC, He WQ, Newall AT, et al. Effectiveness of Acellular Pertussis Vaccine in Older Adults: Nested Matched Case-control Study. Clin Infect Dis 2020; 71:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Versteegen P, Valente Pinto M, Barkoff AM, et al. Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom. EBioMedicine 2021; 65:103247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Havers FP, Moro PL, Hunter P, et al. Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019. MMWR Morb Mortal Wkly Rep 2020; 69:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandeil W, Atanasov P, Avramioti D, et al. The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review. Expert Rev Vaccines 2019; 18:439.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mertsola J, Van Der Meeren O, He Q, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010; 51:656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halperin SA, Donovan C, Marshall GS, et al. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose. J Pediatric Infect Dis Soc 2019; 8:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suryadevara M, Bonville CA, Cibula DA, et al. Pertussis vaccine for adults: Knowledge, attitudes, and vaccine receipt among adults with children in the household. Vaccine 2014; 32:7000.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Calugar A, Ortega-Sánchez IR, Tiwari T, et al. Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers. Clin Infect Dis 2006; 42:981.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baggett HC, Duchin JS, Shelton W, et al. Two nosocomial pertussis outbreaks and their associated costs - King County, Washington, 2004. Infect Control Hosp Epidemiol 2007; 28:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flanagan MP. How to manage a pertussis outbreak in your practice. Fam Pract Manag 2005; 12:31.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. General best practice guidelines for immunization. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html (Accessed on May 16, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004; 39:1802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsyth KD, Wirsing von Konig CH, Tan T, et al. Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine 2007; 25:2634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulloa-Gutierrez R, Hozbor D, Avila-Aguero ML, et al. The global pertussis initiative: Meeting report from the Regional Latin America Meeting, Costa Rica, 5-6 December, 2008. Hum Vaccin 2010; 6:876.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guiso N, Liese J, Plotkin S. The Global Pertussis Initiative: meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010. Hum Vaccin 2011; 7:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guiso N, Wirsing von König CH, Forsyth K, et al. The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010. Vaccine 2011; 29:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherry JD, Tan T, Wirsing von König CH, et al. Clinical definitions of pertussis: Summary of a Global Pertussis Initiative roundtable meeting, February 2011. Clin Infect Dis 2012; 54:1756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Forsyth K, Plotkin S, Tan T, Wirsing von König CH. Strategies to decrease pertussis transmission to infants. Pediatrics 2015; 135:e1475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi JH, Correia de Sousa J, Fletcher M, et al. Improving vaccination rates in older adults and at-risk groups: focus on pertussis. Aging Clin Exp Res 2022; 34:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halhal B, Glick Y, Galor I, et al. Pertussis Outbreak Among Soldiers During Basic Training: The Need for Updated Protocols. Mil Med 2017; 182:355.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Pertussis (Whooping cough). Postexposure antimicrobial prophylaxis. https://www.cdc.gov/pertussis/outbreaks/pep.html (Accessed on August 14, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crameri S, Heininger U. Successful control of a pertussis outbreak in a university children's hospital. Int J Infect Dis 2008; 12:e85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keller MA, Stiehm ER. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 2000; 13:602.
          </a>
         </li>
         <li class="breakAll">
          Pertussis, Parapertussis (Whooping cough). In: Control of Communicable Diseases Manual, 17th ed, Chin J (Ed), American Public Health Association, Washington, DC 2000. p.34.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 8044 Version 77.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10451158" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11837909" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pertussis--United States, 1997-2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28796757" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Summary of Notifiable Infectious Diseases and Conditions - United States, 2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16340941" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17636756" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Antibiotics for whooping cough (pertussis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15876929" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Use of antibiotics in the prevention and treatment of pertussis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3257783" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evidence for a high attack rate and efficacy of erythromycin prophylaxis in a pertussis outbreak in a facility for the developmentally disabled.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1733147" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Prevention of secondary transmission of pertussis in households with early use of erythromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34602522" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Effects of Early Administration of Macrolides on Whooping Cough in Adolescents and Adults: A Single-center Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34602522" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Effects of Early Administration of Macrolides on Whooping Cough in Adolescents and Adults: A Single-center Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10882595" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Morbidity of pertussis in adolescents and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26335770" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Risk factors for pertussis hospitalizations in Australians aged 45 years and over: A population based nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28462763" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30321305" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Severe Pertussis Infections in the United States, 2011-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6300227" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6300227" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6300227" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Bordetella pertussis isolation in general practice: 1977-79 whooping cough epidemic in West Glamorgan.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2885802" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25111234" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical and histologic features of azithromycin-induced liver injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22591294" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Azithromycin and the risk of cardiovascular death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15356306" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Oral erythromycin and the risk of sudden death from cardiac causes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11584995" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Current pharmacotherapy of pertussis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9661039" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10824032" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15996744" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : In vitro activity of telithromycin against Gram-negative bacterial pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25241683" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinical manifestations of children with microbiologically confirmed pertussis infection and antimicrobial susceptibility of isolated strains in a regional hospital in Japan, 2008-2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/215555" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effect of erythromycin and amoxycillin on Bordetella pertussis in the nasopharynx.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9574735" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Susceptibility testing of Bordetella pertussis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29486357" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Antimicrobial susceptibility testing of Finnish Bordetella pertussis isolates collected during 2006-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29346850" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Trends in the Minimum Inhibitory Concentrations of Erythromycin, Clarithromycin, Azithromycin, Ciprofloxacin, and Trimethoprim/Sulfamethoxazole for Strains of Bordetella pertussis isolated in the Czech Republic in 1967-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26113655" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Widespread Bordetella parapertussis Infections-Wisconsin, 2011-2012: Clinical and Epidemiologic Features and Antibiotic Use for Treatment and Prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25243777" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Symptomatic treatment of the cough in whooping cough.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32958373" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Management of chronic refractory cough in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23487373" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23690518" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25941309" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31059566" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : National Outbreak of Pertussis in England, 2011-2012: A Case-control Study Comparing 3-Component and 5-Component Acellular Vaccines With Whole-cell Pertussis Vaccines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1406564" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pertussis vaccination: acellular pertussis vaccine for the fourth and fifth doses of the DTP series update to supplementary ACIP statement. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1741009" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use--supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29702631" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17167397" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16557217" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10395855" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22806592" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Pertussis in older adults: prospective study of risk factors and morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22806592" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Pertussis in older adults: prospective study of risk factors and morbidity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22739778" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - Advisory Committee on Immunization Practices (ACIP), 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21920404" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23196953" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10618527" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10462235" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10715521" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10706957" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Immune responses to pertussis antigens eight years after booster immunization with acellular vaccines in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11090714" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15933223" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16221778" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Efficacy of an acellular pertussis vaccine among adolescents and adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34049735" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31504309" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effectiveness of Acellular Pertussis Vaccine in Older Adults: Nested Matched Case-control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33647770" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31971933" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30887849" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : The burden of pertussis in older adults: what is the role of vaccination? A systematic literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20704493" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29438562" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25454869" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Pertussis vaccine for adults: Knowledge, attitudes, and vaccine receipt among adults with children in the household.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16511764" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Nosocomial pertussis: costs of an outbreak and benefits of vaccinating health care workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17464912" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Two nosocomial pertussis outbreaks and their associated costs - King County, Washington, 2004.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16144224" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : How to manage a pertussis outbreak in your practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16144224" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : How to manage a pertussis outbreak in your practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15578403" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17280745" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20980794" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : The global pertussis initiative: Meeting report from the Regional Latin America Meeting, Costa Rica, 5-6 December, 2008.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21389775" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The Global Pertussis Initiative: meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21168525" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11-12 January 2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22431797" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Clinical definitions of pertussis: Summary of a Global Pertussis Initiative roundtable meeting, February 2011.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25963002" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Strategies to decrease pertussis transmission to infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35001333" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Improving vaccination rates in older adults and at-risk groups: focus on pertussis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28291499" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Pertussis Outbreak Among Soldiers During Basic Training: The Need for Updated Protocols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28291499" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Pertussis Outbreak Among Soldiers During Basic Training: The Need for Updated Protocols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18706842" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Successful control of a pertussis outbreak in a university children's hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11023960" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Passive immunity in prevention and treatment of infectious diseases.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
